https://scholars.lib.ntu.edu.tw/handle/123456789/568665
標題: | Interferon α-2b with and without ribavirin in the treatment of hepatitis B e antigen-positive chronic hepatitis B: A randomized study | 作者: | CHUN-JEN LIU Lai M.-Y. Chao Y.-C. Liao L.-Y. Yang S.-S. Hsiao T.-J. Hsieh T.-Y. Lin C.-L. Hu J.-T. CHI-LING CHEN PEI-JER CHEN JIA-HORNG KAO DING-SHINN CHEN |
公開日期: | 2006 | 卷: | 43 | 期: | 4 | 起(迄)頁: | 742-749 | 來源出版物: | Hepatology | 摘要: | To study whether interferon (IFN) α and ribavirin combination therapy has a beneficial effect for hepatitis B e antigen (HBeAg)-positive chronic hepatitis B, we enrolled 119 such patients in a randomized study. Fifty-nine patients received 5 million units of IFN-α2b daily for 4 weeks followed by 5 million units three times a week for 28 weeks, plus 1,200 mg ribavirin daily. Sixty patients received the same dosage of IFN plus placebo. They were followed up for 24 weeks posttreatment, and 105 patients (88%) completed the entire course of 56 weeks. By intention-to-treat analysis, the rate of combined response (serum hepatitis B virus [HBV] DNA <2.5 pg/mL and HBeAg seroconversion) was 17% versus 25% between the IFN/ribavirin and IFN/placebo group, respectively, at the end of treatment (P = .35) and 25% vs. 20% at the end of follow-up (P = .32). Using quantitative real-time polymerase chain reaction assay, the log(10) reduction of serum HBV DNA was 1.05 ± 1.72 (mean ± SD) versus 1.29 ± 1.91 between the two groups at the end of treatment (P = .49) and was 2.15 ± 2.15 versus 1.21 ± 2.48 at the end of follow-up (P = .04). Prolonged observations in 83 patients suggested that the combined response was 29% (n = 17) versus 20% (n = 12) at 48 weeks after the end of treatment, respectively (P = .17). The safety profile was similar, except that the IFN/ribavirin group had a higher risk of anemia (15% vs. 0%; P = .002). In conclusion, for the treatment of HBeAg-positive chronic hepatitis B, adding ribavirin does not seem to increase the efficacy of IFN. Copyright ? 2006 by the American Association for the Study of Liver Diseases. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-33645989765&doi=10.1002%2fhep.21100&partnerID=40&md5=471229e8f16e0f9d9e7f62067faaaf9e https://scholars.lib.ntu.edu.tw/handle/123456789/568665 |
ISSN: | 0270-9139 | DOI: | 10.1002/hep.21100 | SDG/關鍵字: | hepatitis B(e) antigen; placebo; recombinant alpha2b interferon; ribavirin; virus DNA; adult; anemia; anorexia; article; asthenia; blood analysis; chill; clinical trial; controlled clinical trial; controlled study; dose response; double blind procedure; drug efficacy; drug safety; female; fever; flu like syndrome; headache; hepatitis B; human; leukopenia; major clinical study; malaise; male; myalgia; nausea; priority journal; randomized controlled trial; risk assessment; risk factor; treatment outcome; xerostomia; Adult; Anemia; Antiviral Agents; DNA, Viral; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Genotype; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferon Alfa-2b; Male; Ribavirin; Treatment Outcome |
顯示於: | 臨床醫學研究所 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。